<DOC>
	<DOCNO>NCT00467025</DOCNO>
	<brief_summary>This phase 2 , randomize , double-blind , placebo control , multi-center study estimate improvement progression free survival ( PFS ) evaluate safety tolerability AMG 386 combination sorafenib treatment subject advance clear cell carcinoma kidney .</brief_summary>
	<brief_title>AMG 386 , 20060159 Phase 2 , RCC 1st Line Combination With Sorafenib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Adenomyoepithelioma</mesh_term>
	<mesh_term>Adenocarcinoma , Clear Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Trebananib</mesh_term>
	<criteria>Subjects must histologically confirm metastatic RCC clear cell component Low intermediate risk accord Memorial Sloan Kettering Cancer Center ( MSKCC ) prognostic risk classification . Measurable disease least one unidimensionally measurable lesion per RECIST guideline modification Adequate organ hematological function evidence laboratory study conduct Screening . ECOG 0 1 Disease Related Known history central nervous system metastasis . Previous treatment ( exclude surgery palliative radiotherapy ) advance metastatic renal cell carcinoma Focal radiation therapy palliation pain bony metastasis within 14 day randomization . Medications Currently previously treat inhibitor VEGF . Currently previously treat inhibitor angiopoietin Tie2 . Currently previously treat bevacizumab . General Medical Diagnosis acute pancreatitis . Myocardial infarction , cerebrovascular accident , transient ischemic attack , percutaneous transluminal coronary angioplasty/stent , congestive heart failure , grade 2 great peripheral vascular disease , arrhythmias control outpatient medication , unstable angina within 1 year prior randomization Major surgery within 30 day randomization still recover prior surgery Uncontrolled hypertension define diastolic &gt; 90 mmHg OR systolic &gt; 150 mmHg . Antihypertensive medication permit . Other Other investigational procedure exclude Subject currently enrol yet complete least 30 day since end investigational device drug study ( ) , subject receive investigational agent ( )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Metastatic clear cell carcinoma kidney</keyword>
	<keyword>RCC</keyword>
</DOC>